ArticleJournal of thoracic disease2026
Computed tomography-based tumoral and peritumoral radiomics models for preoperative prediction of the spread through air spaces in patients with clinical stage I pure solid invasive lung adenocarcinoma: a multicenter study.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Spread through air spaces (STAS) is recognized as a novel invasive mode of lung adenocarcinoma (LADC), linked with poorer prognosis and high risk of recurrence. The aim of this study was to develop and evaluate a radiomics nomogram using computed tomography (CT)-based tumoral and peritumoral radiomics features for preoperatively predicting STAS status in clinical stage I pure-solid LADC. Methods: This study retrospectively enrolled 308 individuals with stage I LADC appearing as pure-solid nodules on thin-section CT who underwent surgical resection from three institutions. We randomly split the patients at authors' hospital into a training set (n=174) and internal validation set (n=73) in a ratio of 7:3, while the external validation set consisted of 61 patients from the other two hospitals. The radiomics features extracted from the gross tumor volume (GTV), two types of peritumoral tumor volume (PTV) (5 and 10 mm around the tumor), and their corresponding two types of gross peritumoral tumor volume (GPTV) were utilized to construct five radiomics models, respectively. Univariate and multivariate analyses identified the independent predictors of STAS. The radscore of the radiomics model with optimal performance was integrated with clinical predictor to develop a comprehensive nomogram. Results: The STAS positive status was found in 118 (38.3%) of the 308 patients {female: 54.2%; median [interquartile range (IQR)] age: 65, [57-72] years}. The GPTV10 model achieved the highest area under the curve (AUC) values of 0.741, 0.737 and 0.741 in three cohorts. The multivariate logistic regression (LR) suggested that micropapillary component was the independent risk factor of pathological STAS. The comprehensive model constructed using the GPTV10 radscore and clinical predictor exhibited AUCs of 0.788, 0.748 and 0.783. The decision curve analysis (DCA) revealed that the nomogram had superior capacity for predicting STAS status in LADC. Furthermore, both pathological STAS status and STAS predicted by the combined model stratified patients for prognosis, with 5-year recurrence-free survival (RFS) showing obvious difference between STAS-positive and STAS-negative. Conclusions: Peritumoral features were significantly correlated with STAS status. The integration of radiomics characteristics and clinical factor provided better performance in the prediction of STAS status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.